1:47 PM
 | 
May 16, 2018
 |  BC Extra  |  Company News

Fate, MSKCC expand off-the-shelf cell therapy deal

Memorial Sloan Kettering Cancer Center and Fate Therapeutics Inc. (NASDAQ:FATE) expanded a 2016 deal on Wednesday, granting Fate exclusive rights to additional IP that covers CAR constructs and off-the-shelf CAR T cells.

The existing deal, led by MKSCC Center for Cell Engineering Director Michel Sadelain, focuses on developing off-the-shelf T cell immunotherapies derived from engineered pluripotent cell...

Read the full 269 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >